炎症体
体内
炎症
表型
计算生物学
生物
医学
免疫学
基因
遗传学
作者
Rosalie Matico,Karolien Grauwen,Dhruv Chauhan,Xiaodi Yu,Irini Abdiaj,Suraj Adhikary,Ine Adriaensen,Garcia Molina Aranzazu,Jesús Alcázar,Michela Bassi,Ellen Brisse,Santiago Cañellas,Shubhra Chaudhuri,Francisca Delgado,Alejandro Diéguez-Vázquez,Marc Du Jardin,Victoria Eastham,Michael Finley,Tom P. Jacobs,Ken Keustermans
标识
DOI:10.1038/s44321-024-00181-4
摘要
The NLRP3 inflammasome plays a pivotal role in host defense and drives inflammation against microbial threats, crystals, and danger-associated molecular patterns (DAMPs). Dysregulation of NLRP3 activity is associated with various human diseases, making it an attractive therapeutic target. Patients with NLRP3 mutations suffer from Cryopyrin-Associated Periodic Syndrome (CAPS) emphasizing the clinical significance of modulating NLRP3. In this study, we present the identification of a novel chemical class exhibiting selective and potent inhibition of the NLRP3 inflammasome. Through a comprehensive structure-activity relationship (SAR) campaign, we optimized the lead molecule, compound A, for in vivo applications. Extensive in vitro and in vivo characterization of compound A confirmed the high selectivity and potency positioning compound A as a promising clinical candidate for diseases associated with aberrant NLRP3 activity. This research contributes to the ongoing efforts in developing targeted therapies for conditions involving NLRP3-mediated inflammation, opening avenues for further preclinical and clinical investigations.
科研通智能强力驱动
Strongly Powered by AbleSci AI